Henrique D. Teixeira

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

Emma Guttman‐Yassky, Henrique D. Teixeira, Eric L. Simpson et al. · The Lancet · 2021 · 502 citations

Allergy, Upadacitinib Versus Placebo, Atopic Dermatitis +9

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis

Andrew Blauvelt, Henrique D. Teixeira, Eric L. Simpson et al. · JAMA Dermatology · 2021 · 451 citations · Full text

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

Kristian Reich, Henrique D. Teixeira, Marjolein de Bruin‐Weller et al. · The Lancet · 2021 · 366 citations

Atopic Dermatitis, Medicine, Moderate-to-severe Atopic Dermatitis +9

Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial

Emma Guttman‐Yassky, Diamant Thaçi, Aileen L. Pangan et al. · Journal of Allergy and Clinical Immunology · 2019 · 344 citations · Full text

HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study

Alexa B. Kimball, Jeffrey M. Sobell, Christos C. Zouboulis et al. · Journal of the European Academy of Dermatology and Venereology · 2015 · 189 citations · Full text